Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit related to securities fraud, with investors encouraged to contact legal representation if they have suffered losses [1] Group 1 - The lawsuit allows investors until January 5, 2026, to request appointment as lead plaintiff [1]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [6][7]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [7]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [8]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [9].

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its Inspire V Device, which is intended for the treatment of obstructive sleep apnea [1][3] - The class period for the lawsuit is from August 6, 2024, to August 4, 2025 [1] Allegations - The Inspire V Device was marketed as a groundbreaking product with significant revenue potential, but the launch was poorly received, leading to excess inventory and reluctance from providers to adopt the new treatment [3][4] - Key operational failures were cited, including incomplete training for treatment centers, lack of necessary IT systems, and unpreparedness for insurance claims processing and Medicare reimbursement [4] Financial Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an extended timeline due to undisclosed challenges, resulting in a drastic reduction of its 2025 earnings guidance by over 80%, from $2.20-$2.30 per share to $0.40-$0.50 per share [5] - Following this announcement, the stock price plummeted by $42.04, or more than 32%, from $129.95 to $87.91 per share, erasing $1.2 billion in market capitalization in a single day [5] - From a high of $216.71 per share on September 23, 2024, the stock price has decreased by $127.00, nearly 60%, resulting in billions lost in market capitalization [5]

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor performance of its new sleep apnea device, Inspire V, which has been delayed in launch and has seen poor demand [2][4]. - The company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [2][3]. Company Performance - On August 4, 2025, Inspire disclosed issues with the launch of Inspire V, including inadequate training for treatment centers, software update delays, and excess inventory leading to poor demand [2][4]. - Following the announcement, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, impacting investors negatively [3]. Legal Proceedings - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and prospects during the class period from August 6, 2024, to August 4, 2025 [4][5]. - Investors who purchased Inspire common stock during the class period are encouraged to file a lead plaintiff motion by January 5, 2026 [5].

Group 1 - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3] - The company will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 11:30 a.m. Eastern Time [1][2] - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3]

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to rally in the third quarter, the period with double-digit YTD gains. Major US indices like Russell 1000®, Russell Midcap®, and Russell 2000® reached record highs in the period. In the quarter, the fund’s Investor Class fund ARTSX returned 8.69%, Advisor Class fund APDSX posted a return of 8.75%, and Institutional ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][6]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including its actual market demand and the necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the true details became known [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - A class action securities lawsuit has been filed against Inspire Medical Systems, Inc. due to alleged securities fraud affecting investors between August 6, 2024, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that the launch of Inspire Medical Systems' new product, Inspire V, was unsuccessful due to poor demand and excess inventory at treatment centers, contradicting prior assurances from the company [2] - Allegations include that Inspire Medical Systems failed to complete essential tasks for the product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

INSP SECURITIES ALERT: BFA Law Notifies Inspire Medical Systems, Inc. Investors of Important January 5 Securities Class Action DeadlineNovember 17, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a signifi ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2] Group 1: Lawsuit Details - The lawsuit claims that the company made false statements and concealed the poor demand for its new product, Inspire V, which was launched unsuccessfully due to significant surplus inventory and reluctance from providers to adopt the new treatment [3] - The complaint highlights that the company failed to complete essential tasks for a successful launch, including training and onboarding for treatment center customers, setting up IT systems, updating insurer claims software, and ensuring Medicare reimbursement was in place [3] Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Group 3: Legal Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States [5]